Top MarketRank™ StocksTop MarketRank™NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $57.68 -0.98 (-1.67%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$57.67 -0.01 (-0.02%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BMRN alerts:Sign Up Key Stats Today's Range$57.32▼$58.6450-Day Range$54.08▼$61.9352-Week Range$52.93▼$93.04Volume1.24 million shsAverage Volume2.58 million shsMarket Capitalization$11.08 billionP/E Ratio17.12Dividend YieldN/APrice Target$93.17Consensus RatingModerate Buy Company Overview BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California. Read More BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks100th Percentile Overall ScoreBMRN MarketRank™: BioMarin Pharmaceutical scored higher than 100% of companies evaluated by MarketBeat, and ranked 5th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 18 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth38.41% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 38.41% in the coming year, from $3.15 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 17.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.83.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 17.12, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.27.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.75. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.71% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 15.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.93 Percentage of Shares Shorted2.71% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently decreased by 15.71%, indicating that investor sentiment is improving significantly. News and Social Media4.1 / 5News Sentiment1.42 News SentimentBioMarin Pharmaceutical has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for BioMarin Pharmaceutical this week, compared to 15 articles on an average week.Search Interest35 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat Follows8 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.85% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMRN Stock News HeadlinesOppenheimer Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)August 28 at 11:22 AM | theglobeandmail.comStrong Q2 Results and Pipeline Progress Could Be a Game Changer for BioMarin Pharmaceutical (BMRN)August 28 at 11:22 AM | finance.yahoo.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 29 at 2:00 AM | Brownstone Research (Ad)BioMarin to Participate in Upcoming Investor ConferencesAugust 27 at 9:00 AM | prnewswire.comBernstein Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN)August 25, 2025 | insidermonkey.comBarclays Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a PT of $86August 23, 2025 | msn.comBernstein Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)August 20, 2025 | theglobeandmail.comBioMarin (BMRN) Posts Strong Q2 Growth, Advances Rare Disease ResearchAugust 17, 2025 | msn.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $65.73 at the start of the year. Since then, BMRN shares have decreased by 12.2% and is now trading at $57.68. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings data on Wednesday, February, 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. The biotechnology company had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 21.45% and a trailing twelve-month return on equity of 12.59%. Read the conference call transcript. Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's top institutional shareholders include Vanguard Group Inc. (9.90%), Primecap Management Co. CA (8.21%), Dodge & Cox (7.87%) and Viking Global Investors LP (6.40%). Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Brian Mueller, Charles Greg Guyer, George Eric Davis, Cristin Hubbard, V Bryan Lawlis, Erin Burkhart and Mark J Alles. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Incyte (INCY), NVIDIA (NVDA), Meta Platforms (META), First Solar (FSLR), (MDVN) (MDVN) and Broadcom (AVGO). Company Calendar Last Earnings2/19/2025Today8/28/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,040Year Founded1997Price Target and Rating Average Price Target for BioMarin Pharmaceutical$93.17 High Price Target$126.00 Low Price Target$65.00 Potential Upside/Downside+61.5%Consensus RatingModerate Buy Rating Score (0-4)2.72 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)$3.37 Trailing P/E Ratio17.12 Forward P/E Ratio18.31 P/E Growth0.74Net Income$426.86 million Net Margins21.45% Pretax Margin27.42% Return on Equity12.59% Return on Assets10.13% Debt Debt-to-Equity Ratio0.10 Current Ratio5.56 Quick Ratio3.60 Sales & Book Value Annual Sales$2.85 billion Price / Sales3.88 Cash Flow$3.26 per share Price / Cash Flow17.70 Book Value$31.39 per share Price / Book1.84Miscellaneous Outstanding Shares192,010,000Free Float190,383,000Market Cap$11.08 billion OptionableOptionable Beta0.18 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BMRN) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.